Sittinger Lab: In situ Tissue Engineering

The team of Michael Sittinger has nearly 30 years of experience with pioneering work in the field of 'Tissue Engineering'. Their current work specifically adresses individual translational challenges and missing links for feasibility of regenerative therapies in different clinical research areas.

The research strategy is focused on stimulation of natural endogenous healing which includes technologies in cell isolation, cell culture and cell quality control and controlled delivery of cells or tissue-forming bioactive factors into the patient. Appropriate handling of cells, factors and delivery materials is directed towards safety and quality requirements of the current regulatory framework to enable feasible and cost-efficient regenerative medical products.

The Tissue Engineering team contributes clinical and commercialization translation of regenerative therapies and products of different clinical research areas.

  • Topics include: Tissue Engineering, Cell-Based Therapies, resorbable biomaterials, 3D in-vitro disease models, bioprinting, bioreactors, cell production, local cell and factor release.
  • Team is currently involved in research and development of treatments for degenerative diseases of the heart muscle, articular cartilage, mandibular bone, neurodegenerative-disorder and spinal disc.

Publications

  • CCL25-Supplemented Hyaluronic Acid Attenuates Cartilage Degeneration in a Guinea Pig Model of Knee Osteoarthritis. J Orthop Res. 2019. First in-vivo proof-of-concept for a new treatment of osteoarthritis. This technology is protected by Charité patents.
  • Toward in situ tissue engineering: chemokine-guided stem cell recruitment. Trends Biotechnol. 2014. Review and white paper on principles to use of cell attractants in tissue engineering.
  • Endomyocardial biopsy derived adherent proliferating cells - a potential cell source for cardiac tissue engineering. J Cell Biochem. 2010. Initial discovery of CardAP-cells for myocardial regeneration. These cells meanwhile entered clinical development. This technology is protected by Charité patents.
  • Regenerative medicine: Selecting the right biological scaffold for tissue engineering. Nat Rev Rheumatol. 2014. Practical view on use of biomaterials in tissue engineering.
  • Long-Term Clinical and MRI Results of Matrix-Assisted Autologous Chondrocyte Implantation for Articular Cartilage Defects of the Knee. Cartilage. 2019. 12-years clinical outcome of earlier cartilage development of the team.